Stocks to Watch 06-15-09

EWORLD COMPANIES INCORPORATED (OTC: EWRC)
"Up 600.00% on Friday"

Detailed Quote: http://www.otcpicks.com/quotes/EWRC.php

eWorld Companies, Inc. is an online marketing & advertising technologies company that develops and markets cutting edge technologies using rich media, flash, animation and 3D graphics to help individuals and businesses market and advertise online. eWorld's revenue model consists of seven components: (1) Affiliation Fees, (2) Affiliate Monthly Subscriptions, (3) Affiliate Benefit Subscriptions, (4) Product Sales, (5) Advertising Revenues, (6) Web Development Accounts, and (7) International Licensing Fees.

EWRC News:

June 12 - eWorld Companies, Inc. Releases Major Upgrade of Boomerang Media Station

eWorld Companies, Inc. (OTC: EWRC) announced that it has officially released version 4.0 of its Boomerang Media Station®. Much more than an upgrade, Boomerang 4.0 is a next-generation technology that was completely rebuilt on an entirely new platform to take full advantage of eWorld’s revolutionary and patent-pending Boomerang technology.

Boomerang 4.0 offers three major advantages over previous versions: It has an entirely new menu system, which makes navigation much quicker and more intuitive. It integrates Nexplore search results on thousands of products, generating strong revenue-sharing opportunities for eWorld Affiliates. And it creates the backbone structure of eWorld’s private-label Customized Boomerang Station, which will be available soon to businesses and non-profit organizations of all sizes. Boomerang 4.0 also has a smooth new interface, an updated “look and feel,” and numerous “under the hood” improvements that add speed, robustness, and efficiency to further enhance the user’s experience.

eWorld CEO Henning Morales commented, “This may be the most important announcement that eWorld has made since its inception. Boomerang 4.0 will allow us to monetize our technology in many ways not previously possible, which we believe will contribute significantly to the company’s revenues and bottom line profits. And it opens the door to further commercialization of our technology through our soon-to-be-released Customized Boomerang. We expect to release additional announcements very soon.”

AMERICAN SCIENTIFIC RESOURCES INCORPORATED (OTC: ASFX)
"Up 366.67% on Friday"

Detailed Quote: http://www.otcpicks.com/quotes/ASFX.php

American Scientific Resources, Inc. manufactures and distributes medical products and supplies. The company, also known as Ulster Scientific, is based in New Paltz, New York.

ASFX News:

June 11 - Safety Product Company Sees Increased Online Sales Resulting from H1N1 Flu

Kidz-Med Thermofocus 5-in-1 Non-Contact Thermometer in Demand

Given the World Health Organization (WHO) has just raised the novel influenza A/swine flu pandemic alert to phase 6, its highest pandemic warning level, The Centers for Disease Control and Prevention (CDC) reports that even though U.S. influenza surveillance systems show a decrease in flu activity, outbreaks are ongoing in various parts of the nation, in some cases intensely.

Kidz-Med Inc., a subsidiary of American Scientific Resources, Inc. (OTC: ASFX) and a leading child health and safety product supplier in the US, sees the effects that the flu is having on the nation by experiencing a drastic increase in online sales, namely on the Kidz-Med Thermofocus 5-in-1 Non-Contact Thermometer, from April 1, 2009 through May 15, 2009.

Kidz-Med has fielded an increase in inquiries about its Kidz-Med Thermofocus 5-in-1 from various entities who are preparing to check adults and children for fevers that could possibly result from this current flu outbreak.

The Company's CEO, and pediatric clinician, Dr. Christopher F. Tirotta reacts by saying, "In our history, we have never received $30,000 in online revenue within a month and a half. We attribute our PR, social media and SEO/SEM tactics to enabling people to find us as a go-to resource, and are ecstatic that our products can help during a time when our nation needs it most."

He continues, "Since the pandemic level has been raised, we are expecting to see an increase in customer inquiries and potentially sales."

The Kidz-Med Thermofocus, which was used by medical personnel in Asia during the SARS epidemic, is an ideal instrument to use to diagnose fevers associated with the flu since it has absolutely no contact with the skin, making for a completely hygienic and non-invasive experience; a reading is taken in a second and the thermometer is clinically proven to be accurate and safe.

Kidz-Med is reaching out to let the public know where to go for reliable safety and prevention information and how the Kidz-Med Thermofocus, as well as the Kidz-Med medicine dispenser pacifier, can benefit them during this time.

Dr. Tirotta concludes, "We recommend visiting the Centers for Disease Control and Prevention at http://www.cdc.gov for trusted flu information. Additionally, should anyone have questions pertaining to flu safety prevention, we can be reached via our website at www.kidzmed.com."

ABOUT KIDZ-MED, INC.

A division of American Scientific Resources, Inc., Kidz-Med, Inc., was founded in 1993 by Dr. Christopher F. Tirotta to create children's pre-operative educational videos "A Hospital Trip With Dr. Bip" and "Dr. Bip's New Baby Tips". Today, Kidz-Med, Inc. is leading the pediatric and children's health and safety products industry in innovation by providing the most revolutionary patented family-friendly products sourced from around the globe to help keep children safe and parents reassured.

HARD TO TREAT DISEASES INCORPORATED (OTC: HTDS)
"Up 133.33% on Friday"

Detailed Quote: http://www.otcpicks.com/quotes/HTDS.php

In June 2003, International Foam Solutions, Inc. changed its name to Hard to Treat Diseases, Inc. in connection with the completion of a share exchange agreement with Hard to Treat Diseases and T-19, Inc. Hard to Treat Diseases, Inc. holds the international marketing rights, except South Korea, to Tubercin, a patented immunostimulant developed for combating cancer and rheumatoid arthritis under medical patent. Tubercin promotes good health by enhancing the immune system. The nasal spray would be distributed through major holistic retailers and providers worldwide.

HTDS News:

May 20 - Hard to Treat Diseases, Inc. Reports on New Uses For Ribavirin

Hard to Treat Diseases, Inc. (OTC: HTDS) reports that researchers in its Slavica BioChem division have advised of some significant new advances recently announced regarding the drug Ribavirin; one of the drugs with which they are currently conducting research.

On Wednesday, May 13, 2009, Health and Medicine Magazine reported that:

A ground-breaking Canada-wide clinical trial led by Dr. Katherine Borden, at the Institute for Research in Immunology and Cancer (IRIC) of the Universite de Montreal, has shown that a common anti-viral drug, ribavirin, can be beneficial in the treatment of cancer patients. Published in the journal Blood (First Edition), the study demonstrates that ribavirin suppresses the activities of the eIF4E gene in patients. This gene is dysregulated in 30 percent of cancers including breast, prostate, head and neck, colon and stomach cancer.

Interested readers can view a CTV news report on the story at http://watch.ctv.ca/news/top-picks/old-drug-new-use/#clip173867.

The story is of interest as Slavica BioChem is currently conducting research into the use of Ribavirin for use in the treatment of diseases of the Central Nervous system such as Multiple Sclerosis (MS). Studies conducted involved using a combination of ribavirin and tiazofurin and have shown promising results in test animals to date.

One of the benefits of working with established drugs such as ribavirin, which has been in use approximately twenty years, is that the significant experience and history of the drug make it easier to obtain approval for use in new applications, such as the research that has been conducted by Slavica BioChem.

WINNING BRANDS CORPORATION (OTC: WNBD)
"Up 103.57% on Friday"

Detailed Quote: http://www.otcpicks.com/quotes/WNBD.php

Winning Brands Corporation manufactures Winning Colours® Stain Remover for consumer and commercial use as an eco-responsible alternative to traditional solvents. It is gaining popularity for its remarkable gentleness to skin and delicate surfaces, while still being a powerful and versatile stain remover. Main production takes place at the Grand Rapids, Michigan facility of Surefil LLC. Winning Brands' full product range includes a variety of advanced cleaning solutions, such as its non-toxic SMART™ Wet Cleaning liquid alternative to Perchloroethylene used in dry cleaning, KIND™ Laundry Products and CLEAN1™ — the first choice in outdoor cleaning. The company's mission is to replace hazardous chemicals in widespread use with safer alternatives. The initial focus is on cleaning products.

WNBD News:

June 12 - Winning Brands Chooses Indianapolis for First Launch Into Convenience Stores

Winning Colours Stain Remover Targets Greater Indianapolis for Initial Wave of 100 C-Stores

Winning Brands Corporation (OTC: WNBD) (Frankfurt: WMU.F), manufacturer and marketer of advanced eco cleaning solutions, announced today that the race was on to implement its new marketing program called "The Local 100." The aggressive program identifies specific U.S. urban areas in which Winning Brands intends to establish intense local product placement for its breakthrough stain removing solution called Winning Colours Stain Remover. The "Local 100" method focuses on attaining 100 points of sale over any specified 6 week period in an urban market. Indianapolis is the first target market for the program. July 31st is the date set by which to have Winning Colours Stain Remover available in 100 stores in greater Indianapolis.

Winning Brands CEO Eric Lehner explains the context — "The Local 100 program is designed to create 'hot zones' where Winning Colours Stain Remover can gain traction through sheer exposure. We are focusing on the convenience store category in our 'Local 100' programs for several reasons. Firstly, there are nearly 140,000 such outlets in America today; in other words, they are everywhere. Secondly, within this group, there is a healthy variety of suitable field teams with whom to develop custom fulfillment arrangements. Thirdly, a higher than average proportion of convenience stores are independently owned. This lets the pace of our progress match our own initiative because convenience stores can react faster than conventional retail chains for such a program."

Winning Colours Stain Remover has come to the attention of industry watchers because of Winning Brands' plan to create the world's favourite stain removing solution. Winning Brands Senior Vice-President, Lorne Kelly, remarks, "Customers have become quite enthusiastic about Winning Colours Stain Remover, but we are business realists. Landing on the store shelves across the country is what we need to accomplish as the business method. Then those hot zones can emerge and distribution consolidates into regions. What we must achieve is that Winning Colours Stain Remover is known across America, used across America and becomes its favourite stain removing product. We want to reach the point that people will connect us to the simple but powerful premise — 'Got Stains? Try this!' Our determination is fuelled by the testimonials we receive. Winning Colours is terrific for the millions of stains that happen every day."

The first Local 100 program will feature custom designed Winning Colours Stain Remover 12-pack displays that fit easily on counters. The display packs contain pocket-sized 4 oz bottles that fit into purses, auto glove compartments, tool kits, kitchen drawers, and many situations where space is limited or portability matters. The Manufacturer's Suggest Retail Price (MSRP) for the mini-bottle of concentrate is $3.99. Winning Colours is known to be highly dilutable as a multi-cleaner. The 4 oz bottle can yield between 40-80 ounces of multi-cleaner by mixing with plain water or can be used full strength for stain shots. At the end of July Winning Brands will add the names, addresses and photographs of each of its 100 new Indianapolis outlets to the Winning Brands' Store Locator page at www.WinningBrands.ca.

Mr. Lehner concludes, "The bottom line is that Winning Colours Stain Remover is a universal product. Few products on the market have as many ways in which to be distributed as Winning Colours. This is an example of that fact. We can grow categories; home improvement, grocery, convenience stores, office supply stores, pet stores, wine stores — there are as many ideas as there are stains."

COMBINATORX INCORPORATED (NASDAQ: CRXX)
"Up 14.81% on Friday"

Detailed Quote: http://www.otcpicks.com/quotes/CRXX.php

CombinatoRx, Incorporated (CRXX) is pioneering the new field of synergistic combination pharmaceuticals and has a broad product portfolio in phase 2 clinical development. Going beyond traditional combinations, CombinatoRx creates product candidates with novel mechanisms of action striking at the biological complexities of human disease. The lead programs in the CombinatoRx portfolio are advancing into later stage clinical trials based on the strength of multiple positive phase 2a trial results. This portfolio is internally generated from the CombinatoRx proprietary drug discovery technology which provides a renewable and previously untapped source of novel drug candidates. The Company was founded in 2000 and is located in Cambridge, Massachusetts.

CRXX News:

June 12 - CombinatoRx Presents Full Data on Synavive Phase 2 Knee OA Trial at EULAR 2009

Rapid and Sustained Efficacy Demonstrated with Synavive™

CombinatoRx, Incorporated (Nasdaq: CRXX) announced the presentation of full data on Synavive (CRx-102) Phase 2 knee osteoarthritis (OA) trial (COMET-1) at EULAR 2009, the Annual European Congress of Rheumatology in Copenhagen on June 12, 2009. The presentation, “CRx-102, a dissociated glucocorticoid (GC), and prednisolone provide safe and effective pain relief in knee osteoarthritis (OA) in a placebo-controlled Phase 2 trial (COMET-1)”, Huttner et.al., describes the full, modified intent-to-treat, safety and efficacy results of Synavive in this clinical trial:

* Knee OA efficacy was observed early in treatment and sustained throughout the study in all WOMAC measurement subscales including pain, physical function and stiffness.

* Combination effects of Synavive were observed in comparison to prednisolone alone, especially in those subjects with greater disease burden.

* In comparison to prednisolone alone, reduction in hand OA pain was observed early with Synavive and sustained throughout the study.

Safety was established through 14 weeks of treatment:

* No treatment-related serious adverse events were reported,

* All adverse events, with the exception of headaches, were equally distributed among treatment arms,

* A 12-month safety extension trial (N=141 subjects from COMET-1) is nearing completion.

“It is common for OA patients to go through phases where inflammation is a significant, painful and debilitating component of the disease. Low-dose prednisolone appears to be effective when combined synergistically with dipyridamole to amplify its anti-inflammatory activity. This suggests that there may be a role for Synavive in the treatment of OA, as it may allow for the use of prednisolone at what appear to be safe but still effective dose levels,” said Kenneth Huttner, MD, Medical Director at CombinatoRx. “We look forward to the 12-month safety data which will extend our view of the clean safety profile observed through 14 weeks.”

ABOUT OSTEOARTHRITIS

Osteoarthritis is the most common degenerative joint disease and a frequent cause of physical disability among older adults. According to the Arthritis Foundation, more than 21 million people in the United States suffer from the disease. Osteoarthritis affects the hands, lower back, neck, and weight-bearing joints such as the knees, hips, and foot joints. Symptoms of osteoarthritis range from stiffness and intermittent mild pain to severe joint pain and impaired biomechanical function. Although there is no cure for most forms of osteoarthritis, various therapies can help patients manage symptoms such as NSAIDs, Coxibs, local analgesics, intra-articular corticosteroid injection and/or surgery.

ABOUT SYNAVIVE

Synavive is a novel dissociated glucocorticoid product candidate designed to enhance the anti-inflammatory benefits of glucocorticoids, without associated side effects. Synavive contains the cardiovascular agent, dipyridamole, and a very low dose of the glucocorticoid, prednisolone. Synavive is under development as a uniquely-engineered once-daily aligned-release co-formulation. Synavive is thought to act through a novel multi-target mechanism of action in which dipyridamole synergistically and selectively amplifies prednisolone's anti-inflammatory and immunomodulatory activities by inhibiting key cell mediators of inflammation. In prior proof-of-concept clinical trials, Synavive demonstrated a powerful anti-inflammatory effect and rapid onset of action in patients with osteoarthritis and rheumatoid arthritis and was generally well-tolerated. Synavive is in Phase 2 clinical development for the treatment of immuno-inflammatory conditions.

SMOKEFREE INNOTEC INCORPORATED (OTC: SFIO)
"Up 31.58% on Friday"

Detailed Quote: http://www.otcpicks.com/quotes/SFIO.php

Smokefree Innotec, Inc. is in the business of designing, developing, manufacturing and marketing a hi-tech, nicotine delivery cigarette-like device which is completely smoke-free and tobacco-free. Smokefree Innotec’s products are designed to protect the non-smoker from second hand smoke and all its effects while providing the smoker a way to enjoy a smoke-free cigarette anywhere, including places where smoking is prohibited. Further, our products will allow the smoker to enjoy smoking while not having to worry about the dangers and ill effects of regular cigarette smoking.

SFIO News:

June 3 - Smokefree Innotec Strengthens Position in Europe

Smokefree Innotec, Inc. (OTC: SFIO) announced that it has strengthened its distribution network by adding Netherlands-based V.C.T. bv (Verkoop Centrale van Tabakproducten) as distributor for the Netherlands and its daughter company De Jeager Tobacco bvba in Belgium. VCT is a major independent player in the tobacco industry in the Benelux and manufacturer of 13 cigarette brands. VCT Chief Executive Officer, Mr. Alfons Ravelli, is very interested in positioning Smokefree Innotec’s tobacco innovation, the world’s first totally smoke-free, electronic cigarette and has offered Smokefree Innotec office and warehouse space as well as logistic support in the start-up phase.

Diederik van Duyn, a member of Smokefree Innotec’s advisory board, commented: “We are very excited about VCT joining our team. I have known Mr. Ravelli for many years and his cutting-edge companies are always launching innovative products, like kretek-cigarettes, cigarettes for the ladies market, water-pipe tobacco and now our first smoke-free, tobacco-based, electronic cigarette. I emphasize that the cooperation with a renowned player in the tobacco industry will prove of major importance to the introduction of this tobacco-innovation into Tobacco Retail and Convenience outlets in Western Europe. I expect more tobacco companies to follow in VCT´s steps.”